Johnson & Johnson to start late-stage coronavirus vaccine trial in September with up to 60,000 people

A Johnson & Johnson building is shown in Irvine, California.

Mike Blake | Reuters

Johnson & Johnson plans to begin what would be the largest, late-stage trial testing a potential coronavirus vaccine in September, the company confirmed Thursday.

The phase three trial would enroll up to 60,000 people, according to J&J spokesperson and ClinicalTrials.gov. 

J&J’s trial would be the largest testing a coronavirus vaccine yet. Drug companies Moderna and Pfizer, which both began late-stage trials for their potential coronavirus vaccines last month, said they would enroll around 30,000 participants.

J&J said it is using the same technologies it used to make its experimental Ebola vaccine, which was provided to people in the Democratic Republic of Congo in late 2019. It involves combing genetic material from the coronavirus with a modified adenovirus that is known to cause common colds in humans.

This is a developing story. Please check back for updates.

Leave a Reply

Your email address will not be published. Required fields are marked *